- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
RPG Life Sciences reported robust Q4 FY25 performance, with revenue rising 13% YoY to ₹143.09 Cr and PBT before exceptional items increasing 41% YoY to ₹25.00 Cr. For FY25, revenue grew 12% YoY to ₹653.43 Cr, while PBT rose 28% YoY to ₹150.28 Cr, driven by improved EBITDA margins from 23.3% to 26.4%. The company generated a substantial cash surplus of approximately ₹266 Cr from operations and land assignments, positioning itself well for potential inorganic growth. The Board plans to propose a record dividend of 250% along with a special dividend of 50%.